Full Report
Back to reportsCompany Profile
Shanghai Lepure Biotech Co., Ltd. is indexed in Shanghai under Biomedicine. The table below combines recognition context, peer samples and public references for search and review.
Published 2026-06-12. Use company files, policy notices, patent records and the Chinese source report for original-language verification.
Executive Summary
Shanghai Lepure Biotech Co., Ltd. is indexed in the China Little Giant company database. The profile is associated with Shanghai. The report is grouped under Biomedicine. Recognition context: 2021 3rd batch. Chinese source report date: 2026-06-12. The English brief covers company profile, product direction, industry-chain role, patent and R&D signals, scale indicators and policy-material checkpoints, with internal links to the company page, Chinese source report and related topic hubs.
Company and Recognition Snapshot
Shanghai Lepure Biotech Co., Ltd. is indexed as a national-level Little Giant enterprise in Shanghai. The English profile places the company under Biomedicine and records 2021 3rd batch as the available recognition context.
| Recognition batch | 2021 3rd batch |
| Region | Shanghai |
| Industry | Biomedicine |
| Registered capital | RMB 365.80 million |
| Employee signal | 293 employees |
| Listed status | Not listed |
| Patent signal | 98 patent-related records |
| R&D signal | R&D investment detail not published in the English dataset |
Business and Industry-chain Position
Chinese public records indicate software, systems and digital-technology activity, new-materials activity, testing, inspection and technical-service activity. The recorded industry-chain position is Biomedicine and medical devices / Core components and digital hardware. This places the company in a policy-relevant segment for peer comparison by region, industry and batch.
Technology, Patent and R&D Signals
The public profile records 98 patent-related records. The R&D signal is: R&D investment detail not published in the English dataset. Patent and R&D information should be read with product direction, customer evidence and chain position rather than as isolated threshold items.
Policy-material Review Points
- Verify whether the company's main business, niche market and product evidence all point to Biomedicine.
- Check that patent, R&D, employee and financial fields support the same core product direction.
- Compare the company with peers in the same province, industry and recognition batch before using the profile for supplier screening or policy research.
- Use the linked Chinese source report for original-language evidence and source links.
Original Report and Profile
For the underlying database record, open the English company profile. For full-length analysis, original-language wording and public evidence links, open the Chinese source report.
Peer, chain, region and patent matrices
Region and Batch
Regional Recognition Ladder
Batch-level counts show the province, city and industry recognition rhythm around this company.
| Batch | National | Province | City | Industry |
|---|---|---|---|---|
| 2019 / 1st batch | 248 | 17 | 17 | 32 |
| 2020 / 2nd batch | 1,744 | 63 | 63 | 276 |
| 2021 / 3rd batch | 2,930 | 182 | 181 | 214 |
| 2022 / 4th batch | 4,365 | 272 | 270 | 311 |
| 2023 / 5th batch | 3,671 | 206 | 202 | 292 |
| 2024 / 6th batch | 3,012 | 206 | 203 | 342 |
| 2025 / 7th batch | 3,461 | 215 | 212 | 274 |
Counts come from public company records in the portal database.
Report Snapshot
| Company | Shanghai Lepure Biotech Co., Ltd. |
| Region | Shanghai |
| Industry | Biomedicine |
| Published | 2026-06-12 |
| Chinese report | Open Chinese report |